205 related articles for article (PubMed ID: 10670573)
1. c-Kit and c-kit mutations in mastocytosis and other hematological diseases.
Boissan M; Feger F; Guillosson JJ; Arock M
J Leukoc Biol; 2000 Feb; 67(2):135-48. PubMed ID: 10670573
[TBL] [Abstract][Full Text] [Related]
2. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts.
Féger F; Ribadeau Dumas A; Leriche L; Valent P; Arock M
Int Arch Allergy Immunol; 2002 Feb; 127(2):110-4. PubMed ID: 11919418
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
[TBL] [Abstract][Full Text] [Related]
4. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.
Nagata H; Worobec AS; Oh CK; Chowdhury BA; Tannenbaum S; Suzuki Y; Metcalfe DD
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10560-4. PubMed ID: 7479840
[TBL] [Abstract][Full Text] [Related]
5. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
6. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.
Tsujimura T; Morimoto M; Hashimoto K; Moriyama Y; Kitayama H; Matsuzawa Y; Kitamura Y; Kanakura Y
Blood; 1996 Jan; 87(1):273-83. PubMed ID: 8547652
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
8. Kit signal transduction.
Taylor ML; Metcalfe DD
Hematol Oncol Clin North Am; 2000 Jun; 14(3):517-35. PubMed ID: 10909038
[TBL] [Abstract][Full Text] [Related]
9. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
[TBL] [Abstract][Full Text] [Related]
10. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
Ning ZQ; Li J; McGuinness M; Arceci RJ
Oncogene; 2001 Jul; 20(33):4528-36. PubMed ID: 11494148
[TBL] [Abstract][Full Text] [Related]
11. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His.
Pullarkat VA; Pullarkat ST; Calverley DC; Brynes RK
Am J Hematol; 2000 Dec; 65(4):307-9. PubMed ID: 11074560
[TBL] [Abstract][Full Text] [Related]
12. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.
Gerbaulet A; Wickenhauser C; Scholten J; Peschke K; Drube S; Horny HP; Kamradt T; Naumann R; Müller W; Krieg T; Waskow C; Hartmann K; Roers A
Blood; 2011 Feb; 117(6):2012-21. PubMed ID: 21148330
[TBL] [Abstract][Full Text] [Related]
13. New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors.
Longley BJ; Ma Y; Carter E; McMahon G
Hematol Oncol Clin North Am; 2000 Jun; 14(3):689-95. PubMed ID: 10909046
[TBL] [Abstract][Full Text] [Related]
14. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
15. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
[TBL] [Abstract][Full Text] [Related]
16. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
Cruse G; Metcalfe DD; Olivera A
Immunol Allergy Clin North Am; 2014 May; 34(2):219-37. PubMed ID: 24745671
[TBL] [Abstract][Full Text] [Related]
17. Effects of mutant c-Kit in early myeloid cells.
Ashman LK; Ferrao P; Cole SR; Cambareri AC
Leuk Lymphoma; 1999 Aug; 34(5-6):451-61. PubMed ID: 10492068
[TBL] [Abstract][Full Text] [Related]
18. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
19. Signal transduction by several KIT juxtamembrane domain mutations.
Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
[TBL] [Abstract][Full Text] [Related]
20. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
